FDA greenlights OptiScan's bedside glucose monitoring system

The Food and Drug Adminstration on Wednesday granted market clearance to OptiScan Biomedical Corp.'s OptiScanner 5000 Glucose Monitoring System for use in the surgical intensive care unit.

Here are three things to know.

1. The OptiScanner 5000 is a bedside glucose monitoring system for patients in intensive care settings.

2. The device automatically monitors a patient's glucose values and sets off an alarm when levels are too high or low.

3. Clinicians can also track a patient's glucose levels in real time with the device and view trending data to detect fluctuations.

More articles on supply chain:

This biohacker is creating a recipe book of medicines patients can make at home
Roche taps drug discovery firm to develop new antibiotic classes
The problem with eye drops — and why drug companies won't fix it

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars

>